A phase III randomized trial of gantenerumab in prodromal Alzheimer’s diseasePaulo Fontoura, Susanne Ostrowitzki, Robert Lasser et al.|Alzheimer s Research & Therapy|2017Cited by 568
A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's diseaseGuoqiao Wang, Scott Berry, Chengjie Xiong et al.|Statistics in Medicine|2018Cited by 65
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, David B. Clifford et al.|The Lancet Neurology|2025Cited by 39